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1. Introduction
Induced pluripotent stem (iPS) cells are somatic cells which have been imbued with pluripo‐
tent differentiation potential through some form of artificial treatment. On a general level,
these treatments involve modifications in the expression of keystone genes associated with
pluripotency in embryonic stem cells (ESCs) or their downstream expression products. Despite
the conceptual simplicity of iPS cell technology, the 2006 development of the first iPS cell line
by Yamanaka and Takahashi [1] has led to an exponential increase in the volume of pluripo‐
tency research and a new perspective from which to approach regenerative medicine.
iPS cells are a potential alternative to ESCs in therapeutic contexts, retaining the regenerative
potential of ESCs inherent in pluripotent phenotypes, while bypassing some of the risks
associated with ESC transplants. A number of studies have demonstrated that iPS cells and
ESCs have effectively indistinguishable pluripotent capability, implying that iPS cells maintain
the same therapeutic potential long associated with natural ESCs. However, unlike ESCs, iPS
cells do not carry a risk of immunorejection due to their patient specific nature, and are not
affected by the same ethical concerns as ESCs. As such, iPS cells may actually be preferable to
ESCs in some therapeutic contexts due to reduced risk factors for the patient.
Since Yamanaka’s hallmark 2006 paper and methodology, numerous iPS cell generation
technologies have been developed. Most methods rely upon epigenetic expression of genes
determined to be pluripotency regulators. Expression is most commonly induced through viral
integration into the host genome, though other episomal methods do exist. Non-genetic
induced pluripotency methods generally utilize the downstream expression products of the
same keystone genes to generate the same effect as epigenetic expression, without requiring
the host to transcribe and generate the products independently.
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iPS cells promise a new paradigm in regenerative medicine. Developing iPS technologies have
the potential to generate patient specific stem cells, for use in generating any target phenotype
within the human body for transplant. In the research context as well, iPS cells have the
potential to greatly advance existing disease models. Patient specific iPS cells could be used
to create individualized disease models, potentially allowing for more specialized treatment
of patients. Here, we discuss a number of the technologies in development seeking to fulfill
these promises, as well as their potential applications in both therapeutic and research settings.
2. Canonical methodology
The seminal event in the development of iPS technology, Yamanaka and Takahashi’s 2006
publication demonstrated for the first time that the pluripotent phenotype could be induced
in somatic cells and was not exclusive to ESCs. In their initial approach, Yamanaka et al.
screened 24 genes as potential candidates to induce pluripotency in mouse embryonic
fibroblasts (MEFs). The candidate genes were chosen for their perceived roles in regulating
pluripotencty in ESC cultures. From the initial candidates, four genes were eventually
identified to be necessary for induction of pluripotency, each shown to play a role in ESC
pluripotency regulation: Sox2 [2], Oct4 [3], Klf4, and Myc-c [4], often abbreviated as SOKM.
MEF cultures were transduced using four pMXs-based retroviral vectors, each containing one
of the target transcription factors. MEFs transduced with these factors formed colonies
exhibiting ESC morphology and the pluripotent phenotype, as demonstrated by their differ‐
entiation ability and teratoma formation in vivo.
Groundbreaking as it was, this initial iPS technology had multiple issues preventing imme‐
diate use in downstream applications. Despite its effectiveness, the early SOKM method had
a decidedly low efficacy [1, 5], inhibiting generation of large scale iPS cultures for use in
potential clinical applications or in the laboratory. The viral integration method also presented
challenges, as genome integration could lead to random gene reactivation within the iPS
culture, potentially causing deleterious effects. Myc-c itself acts as a protooncogene, which led
to tumorogenesis in 50% of mice chimeric mice derived using the SOKM method [6]. Com‐
pounded with the risk for random gene reactivation, the use of Myc-c could lead to tumoro‐
genesis in potential patients.
3. Improved epigenetic methods
In the interim since the development of the initial induction methodology, many improve‐
ments and variations on the technology have been made. Most of these improved methods
utilize a similar epigenetic pathway to that of the original study, relying upon the host culture
to express downstream products which induce the pluripotent phenotype. We discuss in brief
some of these improved epigenetic methods, their potential niche applications, and their
delivery vectors.
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3.1. Sox2, Oct4, Lin28, Nanog
Yu et. al. demonstrated in 2007 that iPS cells could be generated from pre-natal and post-natal
fibroblasts without transduction of the protooncogene Myc-c, using a combination of Sox2,
Oct4, Lin28, and Nanog (SOLN). Factors were selected based on their high expression in ESCs,
in comparison to myeloid progenitors. Removal of Myc-c from the gene cocktail eliminated
the risk of transcription factor induced tumorogenesis, overcoming one of the fundamental
issues with Yamanaka and Takahashi’s initial methodology. Additionally, Yu et. al. recognized
the potential usefulness of Nanog in iPS technologies, noting that it could lead to an increased
recovery rate for iPS cell clones generated using the SOLN method. This is potentially due to
Nanog’s action upstream of Oct4 and Sox2. Lin28 did not integrate in one iPS clone from each
of the two cell lines tested, suggesting that while Lin28 may improve efficacy, it is not necessary
for reprogramming [7].
3.2. iPS-S: Sox2, Oct4, Lin28, Nanog, Klf4, Myc-c
Combining the SOLN and SOKM transcription factor cocktails, Liao et al demonstrated in 2008
that the efficacy of transfection could be improved by using all 6 previously demonstrated
transcription factors in a single transduction and deemed their method iPS-S. Combination of
the 6 factors was attempted based on empirical speculation, and proved successful. Trans‐
duced colonies also developed more rapidly, within 17 days post-transduction, as opposed to
26 days using the standard SOLN factors. The iPS-S method also increased efficacy roughly
10 fold, which combined with the more rapid development of iPS colonies, partially addressed
the inefficiency issues with the canonical iPS technology [8]. As with other transcription factor
combinations utilizing Myc-c, the iPS-S method carries with it a risk of tumorogenesis due to
random transgene reactivation, inhibiting the use of iPS-S in some applications.
3.3. Combined epigentic, small-compound, and endogenous expression approaches
One of the first approaches to reduce the number of factors required, it was demonstrated that
treatment with the epigenetic small compound BIX-01294 could substitute transduction of
Sox2 or Oct4, using the traditional SOKM combination, in neural progenitor cells (NPCs) [5].
The study was notable for multiple reasons, both the use of chemical conditions to remove
transcription factors, and the reliance upon endogenous gene expression in the target somatic
cell line. While reliance upon Sox2 expression in NPCs ultimately limits the applicability of
the BIX-OKM combination, it set a precedent for use of endogenous gene expressions to reduce
the number of necessary transcription factors in certain cell lines, potentially allowing for safer,
more efficient iPS generation in specific contexts. This concept was further explored by Kim
et. al., who demonstrated that Oct4 alone was capable of inducing pluripotency in neural stem
cells (NSCs) due to their endogenous expression of Sox2, Myc-c, and Klf4 [9].
Shi et al. improved upon their original small compound approach, eliminating the need for
Myc-c transfection and endogenous Sox2 expression. BIX-01294 and non-genetic calcium
channel agonist BayK8644 were identified via a phenotypic compound screen of known drugs,
and combined with the transduction of Oct4 and Klf4 (OK), were able to induce pluripotency
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in MEFs. The elimination of multiple transcription factors suggests that it may be possible to
further replicate the effects of epigenetic transduction using chemical conditions, reducing the
risk for random gene reactivation and potentially allowing for more controlled iPS generation
temporality [10].
Year Group Vector Transcription Factors
2006 Yamanaka et. al. Retroviral Sox2, Oct4, Klf4, Myc-c
2007 Yu et. al. Lentiviral Sox2, Oct4, LIN28, Nanog
2008 Shi et. al. Retroviral, small-compound * Oct4, Klf4, Myc-c, small-compound BIX-01294
2008 Shi et. al. Retroviral, small-compound Oct4, Klf4, small-compounds BIX-01294, BayK8644
2008 Liao et. al. Lentiviral Sox2, Oct4, Klf4, Myc-c, Lin28, Nanog
2008 Okita et. al. Plasmid Sox2, Oct4, Klf4, Myc-c
2009 Kim et. al. Retroviral * Oct4
2009 Fusaki et. al. Sendai virus Sox2, Oct4, Klf4, Myc-c
2010 Sugaya et. al. Retroviral, plasmid Nanog
Table 1. Epigenetic methods covered in this section: year of publication, vectors used, and required transcription
factors. * Reliant upon endogenous expression of certain somatic cell phenotypes.
3.4. Nanog
While the majority of epigenetic approaches rely upon multiple transcription factors, chemical
conditions, or endogenous expression, we patented technology capable of generating iPS cells
through transfection of Nanog alone in 2006 [11]. Nanog is capable of inducing pluripotency
without the aid of other factors due to its role upstream of Oct4 and Sox2. We demonstrated
this interaction in bone marrow derived mesenchymal stem cells (MSCs), in which Nanog
transfection successfully increased Sox2 and Oct4 levels [12]. Nanog has been demonstrated
to induce pluripotency when delivered through lentiviral or plasmid vectors, providing both
integrated and episomal gene expressions pathways.
Eliminating the need for multiple transcription factors has various benefits. As with other
modified gene cocktails, the elimination of Myc-c greatly reduces the risk of tumorogenesis.
Transfection of a single genetic factor may have higher efficacy than that of multiple factors
and could lead to a lower overall cost per iPS cell generated. The improved efficiency and
reduced cost of this method could allow for more rapid production of iPS cells for use in
therapeutic treatments at a lower eventual cost to the patient.
3.5. Retroviral vectors
Beginning with the seminal paper by Yamanaka and Takahashi, the majority of improved
epigenetic methods have utilized retroviral vectors to deliver their target transcription factors.
In the context of induced pluripotency, retroviral vectors provide a number of distinct
advantages, leading to their widespread use. Due to integration with the host genome,
retroviral vectors are capable of generating stable iPS clones that maintain their phenotype
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over time, unlike some episomal vectors. Retroviral technologies are very mature, allowing
for rapid development of vectors and efficient production of vectors in the laboratory. While
standard retroviral vectors are only capable of infecting dividing cells, the lentiviral subclass
of retroviruses are indeed capable of infecting non-dividing cells, an important consideration
when infecting cell types that divide rarely, such as neurons. A combination of these attributes
makes retroviral vectors a highly functional candidate for iPS cell induction.
However, retroviral vectors and the lentiviral sub-class also have certain inherent risk factors.
Most prominently, viral integration into the host genome can cause random gene reactivation,
as discussed in section 2. Using the original SOKM transcription factors, this risk is exaggerated
due to the protooncogenetic nature of Myc-c. Although various epigenetic methods have
eliminated the necessity of Myc-c, random gene reactivation may still lead to tumorogenesis
and deleterious effects in potential transplant patients. As a case study, an FDA clinical trial
involving the retroviral transduction of non-protooncogenes led to the development of
lymphoma in two patients [13]. Residual expression of transgenes may also lead to phenotypic
expression differences between iPS cells and ESCs, leading to a less accurate model of human
ESCs for research use or some clinical applications [7, 14]. To reduce the risk of random
transgene reactivation and minimize remnant transgene expression, transgenes can be excised
using a Cre/Lox system, as demonstrated by multiple groups [12, 14].
3.6. Plasmid vectors
Episomal factors, by definition, allow for the introduction of genetic factors without integration
into the host genome. A lack of host genome integration inherently removes the risk of random
transgene reactivation associated with viral vectors, but presents functional challenges in some
contexts. The most common type of episomal vector in the context of iPS technology is the
plasmid, a DNA library separate from the host’s nucleic genome, first confirmed as a viable
reprogramming vector using the original SOKM factors [15]. The plasmid method has several
advantages, both in the laboratory and in downstream applications. Plasmids are a well-
developed technology, are very easy to generate in great quantity in the laboratory, and have
a relatively low cost-of-use compared to comparable viral vectors. For these reasons, plasmids
are the favored vector in Yamanaka’s laboratory [16].
The most prominent advantage of plasmids is the lack of integration inherent in episomal
vectors. Although there is a potential for spontaneous integration of transgenes during the
reprogramming process, iPS clones generated from plasmid vectors can be screened to select
only integration-free clones [17]. As such, plasmid vectors are unaffected by issues related to
transgene integration, such as residual transgene expression and random transgene reactiva‐
tion. Although these advantages make plasmids a desirable vector for reprogramming, their
efficacy remains well below that of viral integration, limiting the potential for large scale iPS
cell generation using plasmids [18]. This reduced efficacy could potentially be due to the
temporary nature of plasmids, and the speculated ongoing nature of the reprogramming
process [18]; transcription factor expression may be reduced before the iPS reprogramming
process is complete, altering the stoichiometric balance of factors and ending reprogramming
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in cells that may have otherwise formed colonies. Depending upon the chosen transcription
factor combination and somatic cell phenotype, plasmid transduction may also require
multiple transfections to effectively reprogram cells, increasing the difficulty and labor-
intensiveness of the technique.
3.7. Sendai virus
Sendai virus is widely known to replicate in the cytoplasm of host cells without integrating
into the host genome. As such, it has been widely studied as an efficient expression vector and
is known to effectively express transgene without integration [19-21]. Fusaki et. al. have
demonstrated that a sendai virus vector carrying the four SOKM factors is sufficient to
successfully generate iPS colonies [22]. Sendai virus reprogramming was shown to be as or
more effective than traditional retroviral reprogramming, with a ~1% efficacy. Even though
sendai viruses do not integrate into the genome, the persistence of a viral genome within iPS
clones remains a concern for downstream applications. However, Fusaki et. al. were able to
isolate clones that had no remnant presence of viral genomes. As such, the sendai viral vector
is very attractive for use in downstream clinical applications. In the laboratory, sendai viral
vectors leave something to be desired. Pluripotent gene expression of sendai induced iPS cells
has been shown to degrade over the course of 18-20 passages, making long term iPS clone
maintenance difficult.
4. Non-genetic reprograming methods
Complimenting research into genetic induction of pluripotency, a number of avenues into non-
genetic iPS generation have been studied. Although non-integration epigenetic methods have
been developed, many are inefficient, and cannot completely eliminate the possibility of
Vector Advantages Disadvantages
Retroviral Genome integration allows single transduction iPS
clone generation, well-developed technology,
relatively efficient transduction rates
Genome integration may lead to random gene
reactivation, cannot infect non-dividing cells,
residual transgene expression concerns, can
potentially induce immunogenicity
Lentiviral Genome integration allows single transduction iPS
clone generation, well-developed technology,
relatively efficient transduction rates
Genome integration may lead to random gene
reactivation, residual transgene expression
concerns
Plasmid Produces integration-free iPS clones, relatively low
cost, volume production is easily scalable
Lower efficacy than viral integration methods,
clones must be screened to check for integration
Sendai Virus Produces integration-free iPS clones, relatively
high efficacy
Pluripotent gene expression degrades over the
course of 18-20 passages, clones must be screened
for viral genome remnants
Table 2. Comparison of different epigenetic vector technologies
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genome alteration. Non-genetic induction removes the risk of genetic factor reactivation and
consequent genetic modification inherent with these epigenetic methods. To circumvent
genetic transfection, technologies have been developed which utilize downstream RNA and
protein phases of the desired genetic factors to induce expression.
4.1. mRNA transduction
Warren et. al. have demonstrated that modified mRNAs transcribing for the four SOKM factor
proteins are capable of reprogramming when passed into the cytosol of various human cell
types with a catatonic delivery vehicle [23]. Initially, cytotoxicity of transfected mRNAs
inhibited effective reprogramming, requiring modifications to the mRNA. In a novel approach,
Warren et. al. modified the ribonucleotide bases of vector mRNAs by substituting 5-methyl‐
cytidine for cytidine and pseudouridine for uridine, reducing the immunogenicity of the
mRNAs [24]. Combined with interferon inhibitor media supplements, the modifications
allowed for generation of viable iPS clones.
mRNA induced pluripotent stem (RiPS) cell generation is highly efficient relative to other
technologies, with an efficacy of 1.34% in Warren’s initial study. However, the modified
mRNAs are difficult to generate in the laboratory and the techniques are labor-intensive.
Repeated mRNA administrations are also required, increasing the labor-intensive nature of
the technique and complicating volume production of RiPS clones.
4.2. Protein transduction
Multiple groups have also demonstrated reprogramming utilizing the protein products of the
SOKM factors [25, 26]. In order for the target proteins to pass through a lipid bilayer, both
groups attached each target protein to a cell penetrating peptide (CPP). At this stage, cells are
treated with CPP-conjugated proteins multiple times to ensure a continuous supply of
reprogramming factors. The protein induced pluripotent stem (piPS) cell induction method is
significantly less efficient than epigenetic methods, with an efficacy of ~0.001%. In addition to
the transduction inefficiencies, the temporality of the process is relatively slow and the
multiple treatment protocols are very labor intensive, making volume production of piPS
clones difficult. Although inefficient, the piPS method does eliminate the risk of transgene
reactivation and genome integration, just as the RiPS method.
5. Optimization of induction methods
5.1. Factors affecting efficacy
While each induction method has an inherent relative efficacy, it must be noted that a number
of external factors affect reprogramming efficacy as well. Multiple groups have reported that
O2 concentrations play a role in reprogramming efficacy [27, 28], with hypoxia noted to increase
efficiency. The presence of methylation inhibitors, such as 5‘-azacytidine, in culture medium
have also been noted increase efficiency [29, 30]. Hanna et. al. have also demonstrated that cell
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division rate plays a role in the kinetics of iPS induction [31]. Findings such as these suggest
that the specific culture environment play a major role in pluripotency induction and may
effect downstream development of iPS clones.
Of prominent concern, it has been reasoned that the stoichiometric abundances of reprogram‐
ming factors in relation to one another plays a role in reprogramming efficacy [18]. This
rationale is based upon the differential effects of some pluripotency factors when expressed
in different levels; for instance, expression of Oct4 and Sox2 at median levels can maintain
pluripotency of ESCs, but overexpression of Oct4 can induce differentiation [32]. A similar
action has been demonstrated in the context of iPS induction, in which a threefold increase of
Oct4 increased efficacy, but further increases reduced the efficiency of reprogramming [33].
As such, the ability to monitor and manipulate the stoichiometric expression levels of tran‐
scription factors may play a role in selection of vectors and induction technologies in the future.
iPS cells have recently been shown to possess preferential differentiation based on their somatic
cell origin, referred to as epigenetic memory [34-36]. It is believed that variations in DNA
methylation status allow differentiation preferences to persist beyond the boundaries of
reprogramming. It may be possible to exploit this epigenetic memory to increase the terminal
differentiation efficiency of iPS cells based on the desired differentiated phenotype. By
selecting cells of origin in the same lineage, or tissues known to have limited transdifferentia‐
tion ability into the target cell type, it may be possible to augment the efficacy of current
induction protocols.
5.2. Application specific induced pluripotent stem cells
Until now, the majority of iPS cell research has sought to increase the efficacy at which stable
pluripotent iPS clones could be developed. However, for the optimal production of a desired
differentiated phenotype, solely optimizing the efficacy at which iPS clones can be developed
may not be the best strategy. First touched on by Yamanaka in 2009 as the concept of “func‐
tional pluripotency“ [6], it may be more effective to optimize for the generation of a target
differentiated phenotype in the context of downstream applications. As such, a number of the
efficacy factors mentioned above could be considered and optimized for each target phenotype
and each downstream application.
Until such a time as reprogramming efficacy improves dramatically, the optimization of
reprogramming in the context of specific downstream applications may be a way to increase
efficiency. For each application, specific factors regulate the optimal induction method and
environment, such as the acceptability of genome integration, the temporality in which desired
phenotypes are needed, and the volume in which the target phenotype is required. Based on
application specific factors such as these, it may be optimal to utilize various induction
methods combined with an optimized set of efficacy conditions described above to generate
iPS cell products on an application by application basis, rather than focusing solely on
improving the generation of iPS clones.
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6. Clinical applications
iPS cells can theoretically become any tissue in the body, which opens a number of possibilities
for the use of iPS derived cells in graft and transplant based treatments. A key advantage of
iPS cells is patient-specificity. iPS cells could be generated from a patient’s own somatic cells
and differentiated into the desired phenotype, allowing for an effectively autologous trans‐
plant which attenuates the risk of immunorejection. In the manner, iPS technology can be used
as a pathway of sorts to generate desired tissues for transplant and tissue engineering
applications (Figure 1).
6.1. Acute neurological damage
Induced pluripotent stem cell technologies have provided an exciting avenue for potential
treatment of many neurological diseases, many of which have few treatment options at present.
Among these disorders, acute neurological damage has an exceedingly direct treatment model
through the iPS pathway. In many cases, such as stroke or spinal cord injury, direct trans‐
plantation of neuronal cells derived from patient-specific iPS cells to the damaged region could
potentially aid in convalescence. Studies have already demonstrated functional recovery in
spinal cord injury models of mice treated with iPS derived neuronal cells [37]. Groups have
also confirmed functional recovery in peripheral nerve regions [38] and murine ischemia
models [39, 40], with promising graft cell growth rates in ischemia models, and notable
integration with existing neural networks. These findings show promise for the potential of
iPS cell therapies in acute neurological damage conditions; however, further research is needed
to ascertain the efficacy, safety, and long term effects of such transplantations.
6.2. Parkinson’s disease
Some higher cognitive disorders could also be addressed using similar direct transplantation
therapies. Parkinson’s disease is perhaps the most direct of the higher cognitive disorders to
address in this manner, as the primary cause of functional degradation can be traced to a single
cell phenotype. The loss of dopamine secreting neurons in the substantia nigra region of the
brain has been established as the leading cause of many Parkinson’s symptoms, suggesting
that direct replacement of lost dopamine secreting neurons through iPS cell derived neurons
could aid in recovery. Through the use of various methods, multiple groups have efficiently
differentiated iPS cells into dopaminergic neurons [41, 42], overcoming the first obstacle in the
implementation of a transplantation therapy. In a rodent model, transplantation of dopama‐
nergic neurons and other neuronal phenotypes into Parkinson’s disease model were able to
induce functional recovery [43].
These results demonstrate the potential of iPS cells to provide functional recovery in Parkin‐
son’s disease patients. However, further research is needed to establish the degree of recovery
post-transplant, to improve the efficacy of transplantation, and to assess the long-term benefit
of transplantation. It has been suggested that transplanted neuronal populations derived from
iPS cells of hereditary Parkinson’s patients may be inclined to exhibit similar degenerative
phenotypes after implantation and this potential must be explored.
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Figure 1. Induced pluripotent treatment pathway: Somatic cells are isolated from the patient, reprogrammed into iPS
cells, and then differentiated into the target phenotype for treatment
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6.3. Alzheimer’s disease
Unlike Parkinson’s disease, Alzheimer’s disease cannot be traced to the loss of single cell
phenotype in a distinct region. In Alzheimer’s, damage is diffuse throughout the brain, forming
neurofibrillary tangles characterized by high levels of amyloid precursor protein (APP)
expression. It has been demonstrated that high levels of APP expression influence differen‐
tiation toward the glial phenotype [44], inhibiting direct replacement of neurons through non-
terminally differentiated stem cells. As such, Alzheimer‘s does not lend itself to transplantation
therapy as readily as acute neurological injury or Parkinson’s. However, there is a potential
that transplantation of terminally differentiated neuronal populations derived from iPS cells
could have beneficial effects. Transplanted cells may not necessarily replace damaged neurons,
but increased neurotrophic factor production from transplanted neuronal populations may
have positive effects on patient phenotype.
6.4. Cardiovascular treatments
It has been demonstrated that pluripotent stem cells have the potential to differentiate into
cardiomyocyte [45, 46]. Utilizing a number of various culture conditions, including co-culture
with stromal cells and cytokine supplementation, differentiation into cardiomyocytes can be
made relatively efficient [47]. There is a potential that transplantation of iPS derived cario‐
myocytes may be able to assist patients who have suffered a myocardial infraction, as has been
demonstrated when transplanting other related phenotypes [48]. Studies in a murine model
have shown that transplantation of ESC derived cariomyocytes mitigated the functional
damage of myocardial infraction [49]. Due to the similarity of iPS cell and ESC phenotypes,
there is a potential that similar results would be possible utilizing patient specific iPS cells as
the source of cardiomyocytes.
6.5. Hemophilia
Hemophilia is caused by a genetic mutation that reduces the production of coagulant factor
VIII or XI depending on the type. Therefore, it’s possible that transplantation of iPS derived
endothelial cells which express coagulant factors could correct the hemophilia phenotype
in patients [50]. In a murine model, transplantation of iPS derived endothelial cells positive
for factor VIII expression was able to mitigate the hemophilia A phenotype to a large degree.
Endothelial cells were transplanted by injection directly into the liver of hemophiliac mice
and functionality was assessed by a tail cutting assay. After treatment, mice with transplant‐
ed endothelial cells survived for 3+ months after tail cutting, while control mice died within
hours.  Factor  VIII  expression  was  increased  to  8%-12%  of  normal,  indicating  that  full
restoration  of  factor  VIII  expression  may  not  be  necessary  to  effectively  mitigate  the
hemophilia phenotype [51]. These findings show promise for the development of cell based
therapies to treat hemophilia.
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6.6. Blood supply
Blood supply shortages are an ever-present concern in many regions, leading to demand for
additional sources of red blood cells (RBCs). iPS cells could theoretically be used to generate
RBCs as a supplemental source and it has been demonstrated that iPS cells are capable of direct
erythrocytic differentiation [52]. Although the technology exists, the use of iPS cells to generate
RBCs may not always been practical due to the cost of iPS generation, culture, and subsequent
differentiation. As such, until technologies are developed which allow for industrial scale iPS
cell culture and differentiation, the use of iPS cells to augment the blood supply will be fairly
limited. In certain circumstances, such as a patient in need of a rare blood type in advance of
surgery, generation of iPS derived RBCs may be a viable option for treatment.
7. Research applications
7.1. Disease modeling
Accurate disease modeling is a biotechnological problem of fundamental importance. Most
current disease models rely upon murine model organisms, which are capable of providing
insight, but are less than ideal due to interspecies differences [53]. iPS technologies could allow
for in vitro disease modeling, using cultures isolated from those suffering with a given
condition. If widely applied, patient specific iPS cultures could potentially be created to
analyze the nuances of a disease in a particular patient, determining which course of treatment
would be best. Using skin fibroblasts isolated from a patient with spinal muscular atrophy,
Ebert et. al. demonstrated that iPS derived motor neurons could be effectively grown in culture
and maintained the disease phenotype of the patient [54]. These findings indicate that iPS cells
derived from patients with genetic disorders may exhibit the disease phenotype, allowing for
their use as a disease model.
Similar isolations have also occurred with Parkinson’s patients, in which iPS clones were
generated  from  patients  and  subsequently  differentiated  into  dopamanergic  neurons.
However, in the context of Parkinson’s disease, the disease phenotype was not as readily
presented in vitro  due to the relative age of the neurons. While cultured neurons have a
lifespan in weeks, Parkinson’s develops over a period of years due in conjunction with age
related  factors,  possibly  requiring  a  form  of  artificial  stress  treatment  to  accurately
reproduce  the  phenotype  in  vitro  [14].  However,  early  stage  metabolic  dysfunction  has
already  been  identified  and  corrected  in  vitro  using  neurons  generated  from  familial
Parkinson’s patient derived iPS cells, indicating that some early stage phenotypes may be
identifiable without full phenotypic replication [55]. Alzheimer’s disease, like Parkinson’s,
is strongly influenced by a number of age related factor which complicate the creation of
an accurate model. Recently, Shi et. al. demonstrated one potential approach to this problem
by  using  iPS  cells  derived  from  Down  syndrome  patients.  Down  syndrome  patients
overexpress  a  gene  known  to  encode  for  amyloid  precursor  protein  (APP),  a  major
component of the Alzheimer’s phenotype. Cortical neurons generated from these iPS lines
expressed amyloid aggregates and hyperphosphorylated tau protein, both hallmarks of the
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Alzheimer’s disease phenotype, after months in culture [56]. Utilizing a similar approach,
it may be possible to emulate other age related disease phenotypes through variable gene
expression,  providing a second avenue from which to approach the issue.  iPS line have
also  been  derived  from  Huntington’s  patients,  in  which  differentiated  neurons  main‐
tained some portions of the Huntington’s phenotype [57, 58]. CDKL5 mutant iPS lines have
also  been  generated  from  Rett  syndrome  patients,  and  may  allow  for  investigation  of
CDKL5’s  underlying  mechanism  within  patient  cells  [59].  Amyotrophic  lateral  sclerosis
(ALS)  has  also  been  effectively  modeled  using  an  iPS  line  derived  from  familial  ALS
patients [60].
Once generated, these disease models can provide insight into the underlying mechanisms of
the disease. In vitro research of molecular level cellular mechanisms is much cheaper and more
efficient than similar research in mammal models, potentially allowing for increased research
throughput. Established in vitro models also remove confounding factors related to animal
models, potentially making direct identification of mechanisms easier. In the context of
phenotypic identification and the discovery of underlying mechanisms, it is important to
consider the controls necessary for using these iPS derived disease models. Due to potential
phenotypic differences in iPS clones, even from the same isolation, it would be necessary to
generate models using multiple iPS lines from each patient in a diverse group. This spread
would allow for adequate confirmation that the identified phenotype or mechanism is indeed
consistent for all patients with the disease, rather than an artifact of reprogramming or a trait
specific to a single individual [53].
While these results in summary are very promising, substantial challenges remain before iPS
cell cultures can be used as disease models in every instance. Although diseases with limited
temporal dependency, such as spinal muscular atrophy, and clear monogenic origin, such as
Huntington’s, are replicated relatively easily in vitro, there remain unsolved problems in
replicating diseases influenced by multiple factors. As demonstrated in attempts to replicate
the Parkinson’s phenotype in vitro, time related factors can also play a large role in disease
phenotype, complicating modeling. Other diseases, such as Alzheimer’s, may be dependent
upon cellular interactions between multiple cell phenotypes in addition to age related factors.
The homogenous nature of iPS derived cell cultures complicates accurate replication of these
interactions in vitro. In some cases, it may be possible to model some of these cell to cell
interactions using coculture, as demonstrated in ALS models that incorporate both astrocytes
and neurons [61]. Further research is needed to overcome these barriers before iPS cell based
disease modeling can be exploited to its full potential.
7.2. Drug discovery
As a corollary to disease modeling, drug discovery is a promising research application for iPS
cells. Developing new drugs is exceedingly expensive and many drug candidates are rejected
in the final human trial stage due to toxicology concerns [46]. At present, 90% of all drugs
candidates that enter clinical trials fail to be approved, leading to a low drug candidate to
successful drug ratio [62]. If drugs could be screened for human toxicology earlier in the
development cycle, a number of these candidates could be eliminated earlier, allowing for
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increased funding to more promising drugs. This redistribution of funding could eventually
lead to more drug candidates developed in a more rapid fashion.
To assess for toxicology, iPS clones could be generated from a broad cross-section of potential
patients, representing various patient backgrounds. Due to the immortalized nature of iPS
cultures, these cells could be expanded and maintained indefinitely at relatively low expense
to drug developers. As a consequence of effective cell storage technologies, an iPS clone bank
would only expand overtime, allowing for the aggregation of clones generated during multiple
studies. From these clones, tissues could be generated for toxicology testing early in the
development cycle, potentially identifying toxic drug candidates before further testing takes
place (Figure 2). In this manner, a diverse donor population could effectively provide each
type of human tissue with a relatively small amount of tissue collection.
Using iPS disease models as described above, the effectiveness of new drug therapies could
also be tested in vitro. The overall cost of testing using these in vitro models is less than that of
animal modeling, and could allow large scale screening of potential drug candidates early in
the development cycle. Due to the elimination of certain confounding factors present in animal
models, drug testing in iPS derived disease models may also yield unique insights not
demonstrated using traditional models. The iPS clone bank described above could be expand‐
ed to include similarly diverse clone populations from patients with a specific disease. Similar
to its benefits in toxicology testing, an iPS clone bank could allow for testing on a broad cross-
section of disease patients at a relatively low cost. Recently, studies have utilized iPS disease
models to assess the efficacy of Alzheimer’s disease drug candidates in vitro [56] and to
successfully screen for new drugs to potentially treat ALS [60]. These studies demonstrate the
potential for the use of iPS cells in the context of drug development, both to improve the
efficiency of existing drug development pipelines and to screen for entirely new compounds
in a relatively low cost model.
However, drug discovery and toxicology screening using iPS cells is limited by their ability to
accurately replicate in vivo conditions. As discussed above, the homogenous nature of iPS
cultures neglects many influential factors related to cellular interaction, and the temporally
naive nature of iPS cultures neglects many age related factors. As such, further research is
necessary before iPS derived tissues are suitable for use in toxicology testing. For drug therapy
screening, the current state of disease models as discussed above is a limiting factor. Although
not all diseases can be effectively modeled for screening today, some disorders that have well
characterized iPS models may benefit from broad drug screening in the near future.
8. Conclusion: Challenges to the road ahead
A number of roadblocks remain before iPS cells are ready for the clinic. At present, there still
remains a risk of teratoma formation in the event that a subpopulation of iPS cells is not
terminally differentiated prior to transplantation. In the context of a patient-specific autolo‐
gous treatment using iPS cells, methods must be developed by which iPS cells can be generated
in sufficient quantity, reliably, and in a time frame appropriate for the targeted disease.
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Efficiency remains an issue, especially with regards to technologies that do not integrate
transgenes into the host genome. To address efficiency concerns, it is possible that application
specific optimization of induction technologies could improve the efficacy of current induction
technologies.
As disease models, iPS cells are limited by the neglect of several influential factors. Most
prominently, the homogenous populations derived from iPS cells inherently neglect interac‐
tions between multiple cell phenotypes, and these interactions may be critical to understanding
disease mechanisms [6]. iPS cells could potentially be differentiated into various cell types and
cocultured to replicate interactions between cell types, but it may be difficult to generate an
Figure 2. Drug discovery and toxicology workflow. Somatic cells are isolated from a broad cross section of donors,
reprogrammed, and differentiated into relevant tissues for toxicology screening and drug testing
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accurate interaction model, even with multiple cell types. iPS cell cultures also neglect various
age related factors, which may be particularly problematic in modeling certain diseases. These
same issues act as barriers to the use of iPS cells for drug discovery and toxicology screening,
as both applications rely upon accurate iPS models of in vivo cellular activity.
Induced pluripotent stem cell technologies have progressed rapidly in recent years. Various
induction methods have eliminated or reduced many of the fundamental issues with iPS cells,
opening the door to a variety of possible applications. Though there remain a number of
challenges facing the development of iPS cells in the clinic and the laboratory, the potential
benefits to regenerative medicine are profound.
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